Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Start-ups
BioNTech raises $325 million for mRNA therapy and more
by Ryan Cross
July 12, 2019
| A version of this story appeared in
Volume 97, Issue 28
BioNTech, the German drug company best known for its experimental messenger RNA therapies, has raised $325 million in series B financing to move more of its drug candidates to the clinic and build up its manufacturing capacity. The fast-growing firm had raised about $500 million over the past 2 years from private investors and pharmaceutical collaborators. BioNTech says it needs the money to further build and test its experimental cancer immunotherapies, including antibodies, cell therapies, mRNA therapies, and small molecules.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter